Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/18/19 | Current report filing |
|
42 | ||
| 12/17/19 | Notice of Effectiveness |
|
1 | ||
| 12/17/19 | Current report filing |
|
26 | ||
| 12/13/19 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 12/13/19 | General form of registration statement for all companies including face-amount certificate companies |
|
10 | ||
| 12/13/19 | General form of registration statement for all companies including face-amount certificate companies |
|
173 | ||
| 12/09/19 | SEC-generated letter |
|
1 | ||
| 12/05/19 | General form of registration statement for all companies including face-amount certificate companies |
|
65 | ||
| 11/14/19 | Current report filing |
|
37 | ||
| 11/14/19 | Current report filing |
|
3 |